If restricted to the analysis of patients who were tested for all thrombophilias (n = 2504), the prevalence of thrombophilia did not differ significantly from the initial analysis, corresponding to 497/2504 patients with FVL (20%), 129 patients with prothrombin gene mutation (5.2%), 44 patients with AT deficiency (1.7%), 24 patients with PC deficiency (0.9%), 87 patients with PS deficiency (3.5%), and 84 patients with antiphospholipid antibody syndrome (3.3%). This evidence concerns the gene F2 and thrombophilia.